PROCEPT BIOROBOTICS CORP (PRCT) Fundamental Analysis & Valuation

NASDAQ:PRCT • US74276L1052

Current stock price

23.2 USD
-0.07 (-0.3%)
At close:
23.2 USD
0 (0%)
After Hours:

This PRCT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PRCT Profitability Analysis

1.1 Basic Checks

  • In the past year PRCT has reported negative net income.
  • PRCT had a negative operating cash flow in the past year.
  • PRCT had negative earnings in each of the past 5 years.
  • In the past 5 years PRCT always reported negative operating cash flow.
PRCT Yearly Net Income VS EBIT VS OCF VS FCFPRCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • PRCT has a Return On Assets of -18.81%. This is comparable to the rest of the industry: PRCT outperforms 50.53% of its industry peers.
  • PRCT has a Return On Equity (-26.12%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -18.81%
ROE -26.12%
ROIC N/A
ROA(3y)-20.7%
ROA(5y)-21.61%
ROE(3y)-28.86%
ROE(5y)-30.64%
ROIC(3y)N/A
ROIC(5y)N/A
PRCT Yearly ROA, ROE, ROICPRCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • PRCT has a better Gross Margin (63.70%) than 68.09% of its industry peers.
  • In the last couple of years the Gross Margin of PRCT has grown nicely.
  • The Profit Margin and Operating Margin are not available for PRCT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5YN/A
PRCT Yearly Profit, Operating, Gross MarginsPRCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PRCT Health Analysis

2.1 Basic Checks

  • PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PRCT has been increased compared to 1 year ago.
  • Compared to 5 years ago, PRCT has more shares outstanding
  • Compared to 1 year ago, PRCT has a worse debt to assets ratio.
PRCT Yearly Shares OutstandingPRCT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
PRCT Yearly Total Debt VS Total AssetsPRCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 4.61 indicates that PRCT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.61, PRCT is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.14 indicates that PRCT is not too dependend on debt financing.
  • PRCT has a Debt to Equity ratio of 0.14. This is in the better half of the industry: PRCT outperforms 61.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 4.61
ROIC/WACCN/A
WACC8.81%
PRCT Yearly LT Debt VS Equity VS FCFPRCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 6.85 indicates that PRCT has no problem at all paying its short term obligations.
  • PRCT has a Current ratio of 6.85. This is amongst the best in the industry. PRCT outperforms 86.17% of its industry peers.
  • A Quick Ratio of 5.77 indicates that PRCT has no problem at all paying its short term obligations.
  • PRCT has a better Quick ratio (5.77) than 82.45% of its industry peers.
Industry RankSector Rank
Current Ratio 6.85
Quick Ratio 5.77
PRCT Yearly Current Assets VS Current LiabilitesPRCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PRCT Growth Analysis

3.1 Past

  • PRCT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.84%.
  • Looking at the last year, PRCT shows a very strong growth in Revenue. The Revenue has grown by 37.22%.
  • Measured over the past years, PRCT shows a very strong growth in Revenue. The Revenue has been growing by 109.03% on average per year.
EPS 1Y (TTM)2.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
Revenue 1Y (TTM)37.22%
Revenue growth 3Y60.14%
Revenue growth 5Y109.03%
Sales Q2Q%11.94%

3.2 Future

  • PRCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.77% yearly.
  • The Revenue is expected to grow by 19.41% on average over the next years. This is quite good.
EPS Next Y15.53%
EPS Next 2Y23.75%
EPS Next 3Y21.21%
EPS Next 5Y18.77%
Revenue Next Year21.53%
Revenue Next 2Y23.01%
Revenue Next 3Y21.37%
Revenue Next 5Y19.41%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRCT Yearly Revenue VS EstimatesPRCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
PRCT Yearly EPS VS EstimatesPRCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. PRCT Valuation Analysis

4.1 Price/Earnings Ratio

  • PRCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRCT Price Earnings VS Forward Price EarningsPRCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRCT Per share dataPRCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • PRCT's earnings are expected to grow with 21.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.75%
EPS Next 3Y21.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PRCT Dividend Analysis

5.1 Amount

  • No dividends for PRCT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRCT Fundamentals: All Metrics, Ratios and Statistics

PROCEPT BIOROBOTICS CORP

NASDAQ:PRCT (4/10/2026, 8:00:01 PM)

After market: 23.2 0 (0%)

23.2

-0.07 (-0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-25
Earnings (Next)04-30
Inst Owners103.56%
Inst Owner Change0%
Ins Owners4.35%
Ins Owner Change10.35%
Market Cap1.31B
Revenue(TTM)308.05M
Net Income(TTM)-95.57M
Analysts78.1
Price Target33.58 (44.74%)
Short Float %11.93%
Short Ratio3.75
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-25.4%
Min EPS beat(2)-60.27%
Max EPS beat(2)9.47%
EPS beat(4)3
Avg EPS beat(4)-5.89%
Min EPS beat(4)-60.27%
Max EPS beat(4)17.27%
EPS beat(8)6
Avg EPS beat(8)0.96%
EPS beat(12)8
Avg EPS beat(12)-1.04%
EPS beat(16)10
Avg EPS beat(16)0.9%
Revenue beat(2)1
Avg Revenue beat(2)-9.76%
Min Revenue beat(2)-20.45%
Max Revenue beat(2)0.93%
Revenue beat(4)3
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-20.45%
Max Revenue beat(4)3.23%
Revenue beat(8)7
Avg Revenue beat(8)0.3%
Revenue beat(12)10
Avg Revenue beat(12)0.73%
Revenue beat(16)14
Avg Revenue beat(16)3.39%
PT rev (1m)-37.6%
PT rev (3m)-37.6%
EPS NQ rev (1m)-12.9%
EPS NQ rev (3m)-72.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-24.07%
Revenue NQ rev (1m)-1.23%
Revenue NQ rev (3m)-13.1%
Revenue NY rev (1m)-1.13%
Revenue NY rev (3m)-6.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.25
P/FCF N/A
P/OCF N/A
P/B 3.58
P/tB 3.58
EV/EBITDA N/A
EPS(TTM)-1.71
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS5.46
BVpS6.49
TBVpS6.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.81%
ROE -26.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.7%
FCFM N/A
ROA(3y)-20.7%
ROA(5y)-21.61%
ROE(3y)-28.86%
ROE(5y)-30.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.81%
GM growth 5YN/A
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 146.42%
Cap/Sales 3.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.85
Quick Ratio 5.77
Altman-Z 4.61
F-Score3
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)297.58%
Cap/Depr(5y)200.77%
Cap/Sales(3y)7.84%
Cap/Sales(5y)5.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-51.43%
EPS Next Y15.53%
EPS Next 2Y23.75%
EPS Next 3Y21.21%
EPS Next 5Y18.77%
Revenue 1Y (TTM)37.22%
Revenue growth 3Y60.14%
Revenue growth 5Y109.03%
Sales Q2Q%11.94%
Revenue Next Year21.53%
Revenue Next 2Y23.01%
Revenue Next 3Y21.37%
Revenue Next 5Y19.41%
EBIT growth 1Y-7.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year77.5%
EBIT Next 3Y47.43%
EBIT Next 5YN/A
FCF growth 1Y43.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.63%
OCF growth 3YN/A
OCF growth 5YN/A

PROCEPT BIOROBOTICS CORP / PRCT Fundamental Analysis FAQ

What is the fundamental rating for PRCT stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRCT.


What is the valuation status for PRCT stock?

ChartMill assigns a valuation rating of 1 / 10 to PROCEPT BIOROBOTICS CORP (PRCT). This can be considered as Overvalued.


How profitable is PROCEPT BIOROBOTICS CORP (PRCT) stock?

PROCEPT BIOROBOTICS CORP (PRCT) has a profitability rating of 2 / 10.